Announcements Trials
Browse Landscape

Phase

Phase 2 23Phase 1/2 10Phase 1 4Phase 3 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Interventional × tafasitamab × Clear all
NCT05429268 2026-05-05

firmMIND

Incyte Corporation

Phase 3 Active not recruiting
82 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04824092 2026-04-01

frontMIND

Incyte Corporation

Phase 3 Active not recruiting
899 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04680052 2025-12-22

InMIND

Incyte Corporation

Phase 3 Active not recruiting
654 enrolled 40 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡